Important Notice for Applied Therapeutics Shareholders
The Gross Law Firm has an essential update for shareholders of Applied Therapeutics, Inc. (NASDAQ: APLT) regarding a pending class action lawsuit. All shareholders who acquired shares during the specified class period are encouraged to reach out to ensure they are informed about any potential lead plaintiff opportunities. It’s crucial to understand that participating as a lead plaintiff is not a requirement for shareholders to receive any potential recovery.
Class Action Details and Timeline
Shareholders should note the class action period for this case runs from January 3, 2024, to December 2, 2024. During this timeframe, significant developments occurred that impacted the value of Applied Therapeutics shares. A notable incident took place on November 27, 2024, when the company received a Complete Response Letter (CRL) from the FDA regarding the New Drug Application (NDA) for its lead drug candidate, govorestat. The CRL indicated the FDA had not approved the NDA in its current form, which led to a drastic decline in the stock price.
Impact of FDA Communications
In the wake of the FDA's communication, Applied Therapeutics' stock took a significant dive from a closing price of $10.21 on November 26, 2024, to $8.57 on November 27, 2024. Over the next few days, the price continued to fall further, reaching $2.03 by November 29, 2024, and plummeting to $1.75 per share by December 2, 2024. This stark decline represented a total drop of over 80%. Additionally, following a market close on December 2, Applied Therapeutics disclosed receiving a warning letter from the FDA, which further underscored the severity of the clinical trial issues related to the submitted NDA.
Next Steps for Involved Shareholders
For shareholders eager to partake in this class action, the deadline to register is February 18, 2025. Investors should not hesitate to sign up, as timely registration is crucial. By registering, shareholders will gain access to portfolio monitoring services that provide ongoing updates regarding the progression of the class action. It is vital to understand that there is no financial obligation to participate in this legal action, and registering poses no risk to the shareholders.
Why Choose the Gross Law Firm?
The Gross Law Firm is a renowned class action law firm dedicated to advocating for the rights of investors who have suffered losses due to dishonest business practices, fraud, or misrepresentation. The firm strives to ensure transparent corporate conduct and uphold strong practices that benefit investors. They actively pursue recovery for shareholders impacted by misleading information that artificially inflates a company’s stock value.
Company Contact Information
For further inquiries or need assistance, investors can reach out to The Gross Law Firm:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY 10018
Phone: (646) 453-8903
Frequently Asked Questions
What is the class action lawsuit about?
The lawsuit involves shareholders of Applied Therapeutics, Inc. who may have suffered losses following significant stock price declines due to FDA communications.
What is the deadline to register for the class action?
The deadline to register is February 18, 2025. Shareholders should act promptly to ensure their participation.
Do I need to be a lead plaintiff to recover losses?
No, shareholders can recover losses without the need to be appointed as lead plaintiffs.
How do I register for the class action?
Shareholders can register by contacting The Gross Law Firm directly for further instructions.
What type of support can I expect if I register?
Registered shareholders will be added to a portfolio monitoring service for case updates and have access to legal support throughout the process.
